INTERIM REPORT JANUARY - MARCH 2016
FIRST QUARTER · Net sales amounted to MSEK 82.3 (0.4) · Earnings before depreciation were MSEK 9.3 (-14.9) · Earnings per share amounted to SEK 0.06 (-0.42) · Cash and cash equivalents at period end amounted to MSEK 11.2 (32.2) · The name of the Group was changed to Karo Pharma to better re-flect current operations SIGNIFICANT EVENTS AFTER PERIOD END · Two share issues totaling MSEK 280 were carried out. The issues, which were oversubscribed by 210 per cent, were completed after period end, hence not being reflected in the cash position. Executive Chairman Anders